First quarter, January 1 – March 31, Q1 2025 Group
(figures in parentheses refer to the corresponding period in the previous year)
Net sales amounted to 0 (0).
Other operating income amounted to 1,662 (68) TSEK.
Profit after tax amounted to -10,937 (-8,929) TSEK.
Earnings per share before and after dilution: -0.02 (-0.02) SEK.
Cash flow from operating activities was -9,176 (-8,800) TSEK.
Significant events during the quarter
Prolight received a positive patent decision for core Psyros patent A Notice of Intention to Grant from the European Patent Office (EPO) protects the company’s point-of-care analysis technology for single molecule counting.
Prolight received its second positive patent decision for the Psyros technology The Notice of Intention to Grant from the EPO is an extension of the main application.
Prolight received notice of allowance for the MicroFlex patent Prolight received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application concerning the analytical unit and reaction chamber of the company’s point-of-care analysis system, MicroFlex, which is being developed by Prolight’s partner TTP (The Technology Partnership plc).
Prolight announced positive preclinical data The results show that Prolight is well on track to deliver a high-sensitivity troponin test on the company’s Psyros platform for single molecule counting.
Significant events after the end of the period
Study demonstrates how quickly biomarkers can be integrated into the Psyros POC platform A joint research project between Prolight and cardiologist Dr. Sam McGrath at St Thomas’ Hospital demonstrated how rapidly a test for the cardiac biomarker cMyC can be transferred to the Psyros POC system. The study highlights the platform’s potential and broader diagnostic applications beyond high-sensitivity troponin.
Prolight was granted its first two European patents for the Psyros technology The company’s first two European patents for the Psyros technology for single molecule counting have been officially granted by the European Patent Office (EPO).
Prolight received new MicroFlex patent approval in the US The US Patent and Trademark Office granted Prolight a patent for the analytical unit and reaction chamber of the company’s POC system MicroFlex.
Prolight resolved on a rights issue The proceeds are intended to be used to complete the development of the Psyros system and achieve commercialization, subject to approval at the upcoming extraordinary general meeting.
Notice of extraordinary general meeting in Prolight Diagnostics AB (publ) The meeting will be held at Prolight’s premises at Gasverksgatan 3 A, 222 29 Lund, on Tuesday, June 10, 2025, at 10:00 am CET.
New chairman of the board The nomination committee has nominated Fredrik Alpsten as new board member and chairman of the board for the AGM on June 30, 2025.
